Infant radiant warmers to be reclassified:
This article was originally published in Clinica
The FDA now has sufficient data to propose reclassification of radiant heaters for infants from Class III (premarket approval) to Class II (special controls). Written comments are to be submitted by November 25th to Dockets Management Branch (HFA- 305), Food and Drug Administration, 12420 Parklawn Dr, Rm 1-23, Rockville, Md 20850.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.